Immucell (ICCC) Cash & Equivalents (2010 - 2026)

Immucell (ICCC) has reported Cash & Equivalents for 17 consecutive years, with $8.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents rose 47.71% year-over-year to $8.9 million; the trailing twelve-month figure through Jun 2026 stood at $8.9 million (up 47.71% YoY), and the FY2025 full-year result was $3.8 million, up 1.29% from the prior year.
• Cash & Equivalents improved to $8.9 million in Q2 2026 per ICCC's latest filing, from $3.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $11.8 million in Q1 2022 and bottomed at $960347.0 in Q1 2024.
• Historically, Cash & Equivalents has averaged $4.8 million across 5 years, with a median of $3.8 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents slumped 86.83% in 2023, then jumped 378.93% in 2025.
• Over 5 years, Cash & Equivalents stood at $5.8 million in 2022, then sank by 83.1% to $978741.0 in 2023, then jumped by 283.99% to $3.8 million in 2024, then gained by 1.29% to $3.8 million in 2025, then soared by 132.74% to $8.9 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $8.9 million, $3.8 million, and $3.9 million for Q2 2026, Q4 2025, and Q3 2025 respectively.